CARA News and Press, Cara Therapeutics Inc. From 03/01/22

KORSUVA™ (difelikefalin) injection U.S. commercial launch on track for April 2022 with extensive pre-launch activities completed Initiation of Oral KORSUVA (difelikefalin) Phase 3 pruritus programs in non-dialysis dependent advanced chronic kidney disease and atopic derma...

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics (NASDAQ:CARA) said a committee of the European Medicines Agency’s (EMA) recommended the approval of Kapruvia (difelikefalin) to treat moderate-to-severe pruritus linked with chronic kidney disease in hemodialysis pati...

Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia ® (difelikefalin) as first therapy in Europe for the treatment of chronic kidney disease associated-pruritus (CKD-aP) in hemodialysis patients European Commission decision for EU M...

STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference c...

STAMFORD, Conn., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a virtual rese...

The global launch of Bylvay was more successful than expected and Albireo doubled its net sales guidance for 2021. Beyond Odevixibat, Albireo was able to discover new drugs with blockbuster. Both early clinical assets address a market with a high medical need and have blockbuster ...

STAMFORD, Conn., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that its licensing partner Maruishi ...

STAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President a...

Cara received approval for IV KORSUVA in August. Since then, the stock has gone in circles without any catalysts to help unlock value. 2022 is full of catalysts to help CARA do exactly that. The current valuation doesn't quite price in AD or oral KORSUVA approval. Investors ge...

The Premium Portfolio has gained +6.80% YTD compared to the S&P 500 +21.62% YTD and the Aurum Hedge Fund Industry Index +6.31% with one week to go. The Premium Portfolio compound annual growth rate (CAGR) of +25.57% compares favorably to the S&P 500 of +14.31% CAGR from 2018. ...